A novel oxido-viscosifying Hyaluronic Acid-antioxidant conjugate for osteoarthritis therapy: Biocompatibility assessments

Add time:07/28/2019    Source:sciencedirect.com

To overcome the problem of fast degradation of Hyaluronic Acid (HA) in the treatment of osteoarthritis (OA), HA was protected against the oxidative stress generated by the pathology. Antioxidant conjugated HAs were synthesized and tested in vitro for their resistance in an oxidative environment mimicking OA. HA-4-aminoresorcinol (HA-4AR) displayed the interesting property of increasing in viscosity under oxidative conditions because of crosslinking induced by electron transfer. The novel HA polymer conjugate was shown to be biocompatible in vitro on fibroblast-like synoviocytes extracted from an arthritic patient. This HA conjugate was also assessed in vivo by intra-articular injection in healthy rabbits and was found to be comparable to the native polymer in terms of biocompatibility. This study suggests that HA-4AR is a promising candidate for a next generation viscosupplementation formulation.

We also recommend Trading Suppliers and Manufacturers of Ethyl 6-(hydroxy(oxido)amino)-2-oxo-2H-chromene-3-carboxylate (cas 13373-28-9). Pls Click Website Link as below: cas 13373-28-9 suppliers

Prev:Dioxidomolybdenum(VI) and -tungsten(VI) complexes with tripodal amino bisphenolate ligands as epoxidation and oxo-transfer catalysts
Next:Vanadate complexes of 3-hydroxy-1,2-dimethyl-pyridinone: Speciation, structure and redox properties)